Multiple Companies at Simbay Park Honored as 2024 Shanghai 'Specialized, Sophisticated, Distinctive, and Innovative' SMEs

"Specialized, Precise, Unique, and Innovative" EnterprisesThese refer to small and medium-sized enterprises (SMEs) whose main business and development priorities align with national industrial policies and related requirements. These enterprises possess strong technological innovation and financing capabilities, and demonstrate good development speed, efficiency, and quality. They follow a development path characterized by specialization, refinement, uniqueness, and innovation. Such SMEs are an important support for future industrial chains and a vital force in strengthening and supplementing the chain. "Specialized, refined, unique, and innovative" SMEs achieve specialized, refined, and distinctive development, have strong innovation capabilities, and exhibit high-quality performance, forming the backbone of high-quality SMEs.

The award marks the remarkable achievements made by the park's enterprises in the biopharmaceutical field and symbolizes their leading position in biotechnology.

Park Enterprises

In the new field of epigenetic gene therapy, there are currently only four or five biotechnology companies globally. Epigenic Therapeutics, Inc., established in the second half of 2021, represents China in making its voice heard in this cutting-edge international scientific domain.

Epigenic has currently developed epigenetic regulation tools that can precisely and efficiently regulate the expression of pathogenic target genes without altering the DNA sequence, offering a potential solution to the long-standing safety concerns associated with traditional gene editing. Based on the combination of "epigenetic regulators + precise delivery systems," the Epigenic team has established research pipelines in areas such as metabolic cardiovascular diseases, chronic hepatitis B, ophthalmology, neurodegenerative diseases, and rare diseases. Among these, the first investigational product is about to enter human trials.

UniXelI BIOTECHNOLOGY is a cell drug research and development technology company driven by next-generation stem cell technology. It utilizes a proprietary technology platform for the preparation, culture, differentiation, and gene editing of human pluripotent stem cells to conduct technology research and product development in the field of stem cell therapy. The company provides innovative cell-based therapeutic solutions for neurodegenerative diseases, rare diseases, and other indications, aiming to create a healthier future for humanity through stem cell science.

Currently, the cell therapy technology developed by UniXelI BIOTECHNOLOGY has obtained multiple related international patents. Several research achievements have been published in top international academic journals such as Nature Methods and Cell Stem Cell. The midbrain dopaminergic neural progenitor cell drug developed by UniXelI BIOTECHNOLOGY for the treatment of Parkinson's disease is currently advancing rapidly in IIT trials in collaboration with Shanghai Ruijin Hospital. The IND clinical trial application is expected to be completed in 2024, with plans to initiate participant enrollment in early 2025.

BRC BIOTECHNOLOGY (SHANGHAI) CO., LTD. focuses on compliance quality and safety testing services for biopharmaceuticals.

BRC BIOTECHNOLOGY is dedicated to addressing the urgent needs of biosafety testing, providing professional and compliant biosafety testing, methodology development, target validation evaluation, and related testing kit products. The unique humanized animal platform for stem cell transplantation introduced by BRC BIOTECHNOLOGY has supported innovative target development and validation for several internationally renowned pharmaceutical companies. Its rapid ready-to-use testing technology development platform has completed the development of more than 20 residual nucleic acid testing kit products.

In recent years, Star North·Free Trade Zone No.1 has been adhering to strengthening policy guidance and optimizing precise services, comprehensively promoting the cultivation of specialized, refined, unique, and innovative enterprises.

Next, the park will continue to strengthen the leading role of enterprises in innovation, promote the deep integration of the innovation chain, industry chain, capital chain, and talent chain at a higher level, and continuously improve the policy system, industrial ecosystem, and innovation vitality. It will help enterprises grow and develop in the direction of specialization, refinement, uniqueness, and novelty, contributing to the life and health industry in Pudong New Area.